Literature DB >> 6972765

Immunogenetic control of experimental type II collagen-induced arthritis. I. Susceptibility and resistance among inbred strains of rats.

M M Griffiths, E J Eichwald, J H Martin, C B Smith, C W DeWitt.   

Abstract

Seven inbred rat strains were tested for susceptibility to experimental type II collagen-induced arthritis and for development of cellular immunity to type II collagen by delayed hypersensitivity skin testing. WF (RT1u), LEW (RT1l), and DA (RT1a) were the most susceptible of the strains tested with respect to incidence (greater than 95%) and severity of disease. LEW and DA were strongly skin test reactive to calf type II collagen. BUF (RT1b) developed moderate skin test responses to calf type II collagen and showed low susceptibility to collagen arthritis (1/8). MAXX (RT1n), LEW.B3 (RT1nvl), and AUG (RT1c) were not susceptible to collagen arthritis and showed negative to very weak skin test responses to type II collagen. Disease susceptibility was inherited as a dominant trait in the F1 progeny of (WF X LEW.B3) matings. These data suggest that clinical expression of experimental collagen-induced arthritis and immune responsiveness to type II collagen are controlled in part by genes within or closely linked to the rat major histocompatibility complex--RT1.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6972765     DOI: 10.1002/art.1780240605

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  42 in total

1.  The immune response of guinea-pigs to type II collagen: poor cross-reactivity with homologous type II collagen accounts for resistance to collagen-induced arthritis.

Authors:  A D Hernandez; M A Cremer; A S Townes; J M Stuart; A H Kang
Journal:  Immunology       Date:  1988-04       Impact factor: 7.397

2.  Inhibition by FK506 of established lesions of collagen-induced arthritis in rats.

Authors:  C Arita; T Hotokebuchi; H Miyahara; K Arai; Y Sugioka; N Kaibara
Journal:  Clin Exp Immunol       Date:  1990-12       Impact factor: 4.330

3.  Conformationally constrained peptides from CD2 to modulate protein-protein interactions between CD2 and CD58.

Authors:  Ameya Gokhale; Thomas K Weldeghiorghis; Veena Taneja; Seetharama D Satyanarayanajois
Journal:  J Med Chem       Date:  2011-07-14       Impact factor: 7.446

4.  Peptide motif for the rat MHC class II molecule RT1.Da: similarities to the multiple sclerosis-associated HLA-DRB1*1501 molecule.

Authors:  Hüseyin Duyar; Jörn Dengjel; Katrien L de Graaf; Karl-Heinz Wiesmüller; Stefan Stevanović; Robert Weissert
Journal:  Immunogenetics       Date:  2005-02-12       Impact factor: 2.846

5.  Evaluating candidate autoantigens in rheumatoid arthritis.

Authors:  A P Cope; G Sønderstrup
Journal:  Springer Semin Immunopathol       Date:  1998

6.  Targeting TNF-alpha with a tetravalent mini-antibody TNF-TeAb.

Authors:  Mengyuan Liu; Xiangbin Wang; Changcheng Yin; Zhong Zhang; Qing Lin; Yongsu Zhen; Hualiang Huang
Journal:  Biochem J       Date:  2007-09-01       Impact factor: 3.857

7.  Different effect of cyclosporin A on arthritides induced by a muramyl dipeptide analogue or the complete adjuvant in rats.

Authors:  T Sugawara; S Takada; K Furuhama; S Takayama; M Nomura; M Kato
Journal:  Int J Exp Pathol       Date:  1995-06       Impact factor: 1.925

8.  Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig.

Authors:  D B Knoerzer; R W Karr; B D Schwartz; L J Mengle-Gaw
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

9.  Experimental immune mediated arthritis in rhesus monkeys. A model for human rheumatoid arthritis?

Authors:  N P Bakker; M G van Erck; C Zurcher; P Faaber; A Lemmens; M Hazenberg; R E Bontrop; M Jonker
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

10.  Effect of etodolac on type-II collagen-induced arthritis in mice.

Authors:  K Inoue; A Motonaga; H Suzuka; H Yoshifusa; H Fujisawa; T Nishimura; Y Inoue; F Ueda; Y Shibata; K Kimura
Journal:  Agents Actions       Date:  1993-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.